Results 121 to 130 of about 16,776 (152)
Association Between Discharge Medications and Oncologic Post-Embolization-Syndrome-Related Outcomes. [PDF]
Cancer MedLi H +10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
European Journal of Cancer, 1993
Ondansetron is the first selective antagonist of the 5-hydroxytryptamine receptors (type 3) marketed for the prevention of emesis induced by antineoplastic agents. Ondansetron has been shown to be more active and less toxic than high-dose metoclopramide in patients submitted to cisplatin chemotherapy.
F, Roila +8 more
openaire +3 more sources
Ondansetron is the first selective antagonist of the 5-hydroxytryptamine receptors (type 3) marketed for the prevention of emesis induced by antineoplastic agents. Ondansetron has been shown to be more active and less toxic than high-dose metoclopramide in patients submitted to cisplatin chemotherapy.
F, Roila +8 more
openaire +3 more sources